查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1859887

青光眼治療：全球市場佔有率和排名、總銷售額和需求預測（2025-2031 年）

Glaucoma Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 98 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球青光眼治療市場預計在 2024 年達到 64.78 億美元，預計到 2031 年將達到 87.05 億美元，2025 年至 2031 年的複合年成長率為 4.3%。

青光眼是全球眼科市場中佔比最大的疾病之一。青光眼的治療方法包括眼藥水、口服藥物、雷射手術、傳統手術或這些方法的組合。所有治療的目標都是防止視力喪失，因為青光眼導致的視力喪失是不可逆轉的。幸運的是，如果能夠在早期發現並進行藥物和/或手術治療，青光眼是可以控制的，大多數患者不會出現視力喪失。

人口老化和慢性眼科疾病的累積負擔，持續推動人們對可及的眼壓降低和神經保護療法的需求。緩釋性藥物療法、微創手術方案以及非藥物器材（例如，穿戴式眼壓管理系統和眼壓調節幫浦）的臨床進展和商業化藍圖，已明確納入主要上市公司的中長期策略，從而拓展產品類型並擴大地域覆蓋範圍。已開發市場健全的報銷和法規結構為高品質創新創造了絕佳機遇，而新興市場初級眼科保健水平的提高則為業務擴張提供了助力。能夠將研發成果轉化為合規且可擴展的產品，並建構差異化分銷和服務模式的公司，可望提升商業性價值。

主要挑戰包括嚴格的監管要求和對臨床證據的渴望，需要證明安全性和有效性的長期持久性，以及難以將研究結果與實際應用和療效聯繫起來。新型器械和給藥系統通常需要漫長的臨床試驗和與監管機構的密切互動，這可能會延緩商業化進程並增加成本。供應鏈的穩健性、原料的採購以及先進的製造能力是規模化生產的重要風險因素。監管機構高度重視病患體驗和長期監測，尤其是在老年病患中，上市後問題可能導致備受矚目的合規性和聲譽風險。

終端使用者的需求正從單純的療效轉向全面的治療體驗。病人和醫療服務提供者優先考慮用藥的便利性、減輕長期負擔、合併症管理以及整體治療成本。醫院和專科診所正積極採用可重複使用的手術輔助工具、配套的手術產品以及與臨床路徑整合的服務相關解決方案。居家醫療和遠端監測的發展趨勢正迫使製造商在設計產品時更加重視易用性和數位化連接性。雖然傳統的經銷通路和機構採購仍然重要，但直接面向患者的數位化管道和零售管道正在成長，這使得品牌和終端用戶教育的重要性日益凸顯。

本報告旨在對全球青光眼治療市場進行全面分析，重點關注總收入、市場佔有率和主要企業的排名，以及按地區/國家、產品和應用對青光眼治療進行分析。

青光眼治療市場規模、估算和預測以銷售收入為指標，以 2024 年為基準年，並包含 2020 年至 2031 年的歷史數據和預測數據。透過定量和定性分析，旨在幫助讀者制定業務/成長策略，評估市場競爭格局，分析公司在當前市場中的地位，並就青光眼治療做出明智的商業決策。

市場區隔

公司

  • Novartis
  • AbbVie
  • Pfizer
  • Akorn
  • Teva
  • Bausch & Lomb
  • Otsuka Pharmaceutical
  • Santen
  • Lunan Pharma
  • Zizhu Pharma

產品細分

  • 前列腺素類似物（PGA）
  • BETA阻斷劑
  • α-促效劑
  • 其他

應用領域

  • 診所
  • 藥局
  • 其他

按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for Glaucoma Treatment was estimated to be worth US$ 6478 million in 2024 and is forecast to a readjusted size of US$ 8705 million by 2031 with a CAGR of 4.3% during the forecast period 2025-2031.

Glaucoma is one of the largest segments in the global ophthalmic market. Glaucoma can be treated with eye drops, pills, laser surgery, traditional surgery or a combination of these methods. The goal of any treatment is to prevent loss of vision, as vision loss from glaucoma is irreversible. The good news is that glaucoma can be managed if detected early, and that with medical and/or surgical treatment, most people with glaucoma will not lose their sight.

The accumulated burden of aging populations and chronic ophthalmic conditions is driving persistent demand for accessible IOP lowering and neuroprotective therapies. Clinical advances and commercialization roadmaps in sustained-release pharmacotherapies, minimally invasive surgical options and non-pharmacologic devices (such as wearable IOP management systems and pressure-adjusting pumps) have been explicitly incorporated into the medium- and long-term strategies of major listed players, expanding product categories and enabling geographic penetration. Robust reimbursement and regulatory frameworks in developed markets create premium opportunities for high-quality innovations, while improvements in primary eye care in emerging markets offer expansion levers. Companies that can translate R&D into compliant, scalable products and build differentiated channel and service models stand to amplify commercial value.

Key challenges include onerous regulatory and clinical evidence requirements, the need to demonstrate durable long-term safety and efficacy, and the difficulty of translating trial results into real-world adherence and outcomes. Novel devices and delivery systems often require prolonged clinical programs and intensive regulatory dialogue, which slows commercialization and raises costs; supply chain robustness, material sourcing and advanced manufacturing capability are critical risks for scale-up. Regulators place particular emphasis on patient experience and long-term surveillance in older populations; post-market issues can lead to high-visibility compliance and reputational risks.

End-user demand is shifting from pure efficacy toward a complete treatment experience: patients and providers prioritize dosing convenience, lowered long-term burden, comorbidity management and total cost of care. Hospitals and specialty clinics are receptive to reusable surgical adjuncts, complementary procedural products and service-linked solutions integrated with clinical pathways; home care and remote monitoring trends push manufacturers to design for usability and digital connectivity. Traditional distribution and institutional procurement remain significant, but direct-to-patient digital channels and retail are growing, elevating the importance of brand and end-user education.

This report aims to provide a comprehensive presentation of the global market for Glaucoma Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Glaucoma Treatment by region & country, by Product, and by Application.

The Glaucoma Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Glaucoma Treatment.

Market Segmentation

By Company

  • Novartis
  • AbbVie
  • Pfizer
  • Akorn
  • Teva
  • Bausch & Lomb
  • Otsuka Pharmaceutical
  • Santen
  • Lunan Pharma
  • Zizhu Pharma

Segment by Product

  • Prostaglandin Analogs (PGAs)
  • Beta Blocker
  • Alpha Agonist
  • Others

Segment by Application

  • Clinic
  • Pharmacy
  • Other

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Glaucoma Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Product, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Glaucoma Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Glaucoma Treatment in country level. It provides sigmate data by Product, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Glaucoma Treatment Product Introduction
  • 1.2 Global Glaucoma Treatment Market Size Forecast (2020-2031)
  • 1.3 Glaucoma Treatment Market Trends & Drivers
    • 1.3.1 Glaucoma Treatment Industry Trends
    • 1.3.2 Glaucoma Treatment Market Drivers & Opportunity
    • 1.3.3 Glaucoma Treatment Market Challenges
    • 1.3.4 Glaucoma Treatment Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Glaucoma Treatment Players Revenue Ranking (2024)
  • 2.2 Global Glaucoma Treatment Revenue by Company (2020-2025)
  • 2.3 Key Companies Glaucoma Treatment Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Glaucoma Treatment Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Glaucoma Treatment
  • 2.6 Glaucoma Treatment Market Competitive Analysis
    • 2.6.1 Glaucoma Treatment Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Glaucoma Treatment Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glaucoma Treatment as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Product

  • 3.1 Introduction by Product
    • 3.1.1 Prostaglandin Analogs (PGAs)
    • 3.1.2 Beta Blocker
    • 3.1.3 Alpha Agonist
    • 3.1.4 Others
  • 3.2 Global Glaucoma Treatment Sales Value by Product
    • 3.2.1 Global Glaucoma Treatment Sales Value by Product (2020 VS 2024 VS 2031)
    • 3.2.2 Global Glaucoma Treatment Sales Value, by Product (2020-2031)
    • 3.2.3 Global Glaucoma Treatment Sales Value, by Product (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Clinic
    • 4.1.2 Pharmacy
    • 4.1.3 Other
  • 4.2 Global Glaucoma Treatment Sales Value by Application
    • 4.2.1 Global Glaucoma Treatment Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Glaucoma Treatment Sales Value, by Application (2020-2031)
    • 4.2.3 Global Glaucoma Treatment Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Glaucoma Treatment Sales Value by Region
    • 5.1.1 Global Glaucoma Treatment Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Glaucoma Treatment Sales Value by Region (2020-2025)
    • 5.1.3 Global Glaucoma Treatment Sales Value by Region (2026-2031)
    • 5.1.4 Global Glaucoma Treatment Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Glaucoma Treatment Sales Value, 2020-2031
    • 5.2.2 North America Glaucoma Treatment Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Glaucoma Treatment Sales Value, 2020-2031
    • 5.3.2 Europe Glaucoma Treatment Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Glaucoma Treatment Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Glaucoma Treatment Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Glaucoma Treatment Sales Value, 2020-2031
    • 5.5.2 South America Glaucoma Treatment Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Glaucoma Treatment Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Glaucoma Treatment Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Glaucoma Treatment Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Glaucoma Treatment Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Glaucoma Treatment Sales Value, 2020-2031
    • 6.3.2 United States Glaucoma Treatment Sales Value by Product (%), 2024 VS 2031
    • 6.3.3 United States Glaucoma Treatment Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Glaucoma Treatment Sales Value, 2020-2031
    • 6.4.2 Europe Glaucoma Treatment Sales Value by Product (%), 2024 VS 2031
    • 6.4.3 Europe Glaucoma Treatment Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Glaucoma Treatment Sales Value, 2020-2031
    • 6.5.2 China Glaucoma Treatment Sales Value by Product (%), 2024 VS 2031
    • 6.5.3 China Glaucoma Treatment Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Glaucoma Treatment Sales Value, 2020-2031
    • 6.6.2 Japan Glaucoma Treatment Sales Value by Product (%), 2024 VS 2031
    • 6.6.3 Japan Glaucoma Treatment Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Glaucoma Treatment Sales Value, 2020-2031
    • 6.7.2 South Korea Glaucoma Treatment Sales Value by Product (%), 2024 VS 2031
    • 6.7.3 South Korea Glaucoma Treatment Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Glaucoma Treatment Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Glaucoma Treatment Sales Value by Product (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Glaucoma Treatment Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Glaucoma Treatment Sales Value, 2020-2031
    • 6.9.2 India Glaucoma Treatment Sales Value by Product (%), 2024 VS 2031
    • 6.9.3 India Glaucoma Treatment Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Novartis
    • 7.1.1 Novartis Profile
    • 7.1.2 Novartis Main Business
    • 7.1.3 Novartis Glaucoma Treatment Products, Services and Solutions
    • 7.1.4 Novartis Glaucoma Treatment Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Novartis Recent Developments
  • 7.2 AbbVie
    • 7.2.1 AbbVie Profile
    • 7.2.2 AbbVie Main Business
    • 7.2.3 AbbVie Glaucoma Treatment Products, Services and Solutions
    • 7.2.4 AbbVie Glaucoma Treatment Revenue (US$ Million) & (2020-2025)
    • 7.2.5 AbbVie Recent Developments
  • 7.3 Pfizer
    • 7.3.1 Pfizer Profile
    • 7.3.2 Pfizer Main Business
    • 7.3.3 Pfizer Glaucoma Treatment Products, Services and Solutions
    • 7.3.4 Pfizer Glaucoma Treatment Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Pfizer Recent Developments
  • 7.4 Akorn
    • 7.4.1 Akorn Profile
    • 7.4.2 Akorn Main Business
    • 7.4.3 Akorn Glaucoma Treatment Products, Services and Solutions
    • 7.4.4 Akorn Glaucoma Treatment Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Akorn Recent Developments
  • 7.5 Teva
    • 7.5.1 Teva Profile
    • 7.5.2 Teva Main Business
    • 7.5.3 Teva Glaucoma Treatment Products, Services and Solutions
    • 7.5.4 Teva Glaucoma Treatment Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Teva Recent Developments
  • 7.6 Bausch & Lomb
    • 7.6.1 Bausch & Lomb Profile
    • 7.6.2 Bausch & Lomb Main Business
    • 7.6.3 Bausch & Lomb Glaucoma Treatment Products, Services and Solutions
    • 7.6.4 Bausch & Lomb Glaucoma Treatment Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Bausch & Lomb Recent Developments
  • 7.7 Otsuka Pharmaceutical
    • 7.7.1 Otsuka Pharmaceutical Profile
    • 7.7.2 Otsuka Pharmaceutical Main Business
    • 7.7.3 Otsuka Pharmaceutical Glaucoma Treatment Products, Services and Solutions
    • 7.7.4 Otsuka Pharmaceutical Glaucoma Treatment Revenue (US$ Million) & (2020-2025)
    • 7.7.5 Otsuka Pharmaceutical Recent Developments
  • 7.8 Santen
    • 7.8.1 Santen Profile
    • 7.8.2 Santen Main Business
    • 7.8.3 Santen Glaucoma Treatment Products, Services and Solutions
    • 7.8.4 Santen Glaucoma Treatment Revenue (US$ Million) & (2020-2025)
    • 7.8.5 Santen Recent Developments
  • 7.9 Lunan Pharma
    • 7.9.1 Lunan Pharma Profile
    • 7.9.2 Lunan Pharma Main Business
    • 7.9.3 Lunan Pharma Glaucoma Treatment Products, Services and Solutions
    • 7.9.4 Lunan Pharma Glaucoma Treatment Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Lunan Pharma Recent Developments
  • 7.10 Zizhu Pharma
    • 7.10.1 Zizhu Pharma Profile
    • 7.10.2 Zizhu Pharma Main Business
    • 7.10.3 Zizhu Pharma Glaucoma Treatment Products, Services and Solutions
    • 7.10.4 Zizhu Pharma Glaucoma Treatment Revenue (US$ Million) & (2020-2025)
    • 7.10.5 Zizhu Pharma Recent Developments

8 Industry Chain Analysis

  • 8.1 Glaucoma Treatment Industrial Chain
  • 8.2 Glaucoma Treatment Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Glaucoma Treatment Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Glaucoma Treatment Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Glaucoma Treatment Market Trends
  • Table 2. Glaucoma Treatment Market Drivers & Opportunity
  • Table 3. Glaucoma Treatment Market Challenges
  • Table 4. Glaucoma Treatment Market Restraints
  • Table 5. Global Glaucoma Treatment Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Glaucoma Treatment Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Glaucoma Treatment Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Glaucoma Treatment Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Glaucoma Treatment
  • Table 10. Global Glaucoma Treatment Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glaucoma Treatment as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Glaucoma Treatment Sales Value by Product: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Glaucoma Treatment Sales Value by Product (2020-2025) & (US$ Million)
  • Table 15. Global Glaucoma Treatment Sales Value by Product (2026-2031) & (US$ Million)
  • Table 16. Global Glaucoma Treatment Sales Market Share in Value by Product (2020-2025)
  • Table 17. Global Glaucoma Treatment Sales Market Share in Value by Product (2026-2031)
  • Table 18. Global Glaucoma Treatment Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Glaucoma Treatment Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Glaucoma Treatment Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Glaucoma Treatment Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Glaucoma Treatment Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Glaucoma Treatment Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Glaucoma Treatment Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Glaucoma Treatment Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Glaucoma Treatment Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Glaucoma Treatment Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Glaucoma Treatment Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Glaucoma Treatment Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Glaucoma Treatment Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Novartis Basic Information List
  • Table 32. Novartis Description and Business Overview
  • Table 33. Novartis Glaucoma Treatment Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Glaucoma Treatment Business of Novartis (2020-2025)
  • Table 35. Novartis Recent Developments
  • Table 36. AbbVie Basic Information List
  • Table 37. AbbVie Description and Business Overview
  • Table 38. AbbVie Glaucoma Treatment Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Glaucoma Treatment Business of AbbVie (2020-2025)
  • Table 40. AbbVie Recent Developments
  • Table 41. Pfizer Basic Information List
  • Table 42. Pfizer Description and Business Overview
  • Table 43. Pfizer Glaucoma Treatment Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Glaucoma Treatment Business of Pfizer (2020-2025)
  • Table 45. Pfizer Recent Developments
  • Table 46. Akorn Basic Information List
  • Table 47. Akorn Description and Business Overview
  • Table 48. Akorn Glaucoma Treatment Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Glaucoma Treatment Business of Akorn (2020-2025)
  • Table 50. Akorn Recent Developments
  • Table 51. Teva Basic Information List
  • Table 52. Teva Description and Business Overview
  • Table 53. Teva Glaucoma Treatment Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Glaucoma Treatment Business of Teva (2020-2025)
  • Table 55. Teva Recent Developments
  • Table 56. Bausch & Lomb Basic Information List
  • Table 57. Bausch & Lomb Description and Business Overview
  • Table 58. Bausch & Lomb Glaucoma Treatment Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Glaucoma Treatment Business of Bausch & Lomb (2020-2025)
  • Table 60. Bausch & Lomb Recent Developments
  • Table 61. Otsuka Pharmaceutical Basic Information List
  • Table 62. Otsuka Pharmaceutical Description and Business Overview
  • Table 63. Otsuka Pharmaceutical Glaucoma Treatment Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Glaucoma Treatment Business of Otsuka Pharmaceutical (2020-2025)
  • Table 65. Otsuka Pharmaceutical Recent Developments
  • Table 66. Santen Basic Information List
  • Table 67. Santen Description and Business Overview
  • Table 68. Santen Glaucoma Treatment Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in Glaucoma Treatment Business of Santen (2020-2025)
  • Table 70. Santen Recent Developments
  • Table 71. Lunan Pharma Basic Information List
  • Table 72. Lunan Pharma Description and Business Overview
  • Table 73. Lunan Pharma Glaucoma Treatment Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in Glaucoma Treatment Business of Lunan Pharma (2020-2025)
  • Table 75. Lunan Pharma Recent Developments
  • Table 76. Zizhu Pharma Basic Information List
  • Table 77. Zizhu Pharma Description and Business Overview
  • Table 78. Zizhu Pharma Glaucoma Treatment Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in Glaucoma Treatment Business of Zizhu Pharma (2020-2025)
  • Table 80. Zizhu Pharma Recent Developments
  • Table 81. Key Raw Materials Lists
  • Table 82. Raw Materials Key Suppliers Lists
  • Table 83. Glaucoma Treatment Downstream Customers
  • Table 84. Glaucoma Treatment Distributors List
  • Table 85. Research Programs/Design for This Report
  • Table 86. Key Data Information from Secondary Sources
  • Table 87. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Glaucoma Treatment Product Picture
  • Figure 2. Global Glaucoma Treatment Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Glaucoma Treatment Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Glaucoma Treatment Report Years Considered
  • Figure 5. Global Glaucoma Treatment Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Glaucoma Treatment Revenue in 2024
  • Figure 7. Glaucoma Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Prostaglandin Analogs (PGAs) Picture
  • Figure 9. Beta Blocker Picture
  • Figure 10. Alpha Agonist Picture
  • Figure 11. Others Picture
  • Figure 12. Global Glaucoma Treatment Sales Value by Product (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 13. Global Glaucoma Treatment Sales Value Market Share by Product, 2024 & 2031
  • Figure 14. Product Picture of Clinic
  • Figure 15. Product Picture of Pharmacy
  • Figure 16. Product Picture of Other
  • Figure 17. Global Glaucoma Treatment Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 18. Global Glaucoma Treatment Sales Value Market Share by Application, 2024 & 2031
  • Figure 19. North America Glaucoma Treatment Sales Value (2020-2031) & (US$ Million)
  • Figure 20. North America Glaucoma Treatment Sales Value by Country (%), 2024 VS 2031
  • Figure 21. Europe Glaucoma Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 22. Europe Glaucoma Treatment Sales Value by Country (%), 2024 VS 2031
  • Figure 23. Asia Pacific Glaucoma Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 24. Asia Pacific Glaucoma Treatment Sales Value by Region (%), 2024 VS 2031
  • Figure 25. South America Glaucoma Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 26. South America Glaucoma Treatment Sales Value by Country (%), 2024 VS 2031
  • Figure 27. Middle East & Africa Glaucoma Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 28. Middle East & Africa Glaucoma Treatment Sales Value by Country (%), 2024 VS 2031
  • Figure 29. Key Countries/Regions Glaucoma Treatment Sales Value (%), (2020-2031)
  • Figure 30. United States Glaucoma Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 31. United States Glaucoma Treatment Sales Value by Product (%), 2024 VS 2031
  • Figure 32. United States Glaucoma Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 33. Europe Glaucoma Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. Europe Glaucoma Treatment Sales Value by Product (%), 2024 VS 2031
  • Figure 35. Europe Glaucoma Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 36. China Glaucoma Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 37. China Glaucoma Treatment Sales Value by Product (%), 2024 VS 2031
  • Figure 38. China Glaucoma Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 39. Japan Glaucoma Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 40. Japan Glaucoma Treatment Sales Value by Product (%), 2024 VS 2031
  • Figure 41. Japan Glaucoma Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 42. South Korea Glaucoma Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. South Korea Glaucoma Treatment Sales Value by Product (%), 2024 VS 2031
  • Figure 44. South Korea Glaucoma Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 45. Southeast Asia Glaucoma Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. Southeast Asia Glaucoma Treatment Sales Value by Product (%), 2024 VS 2031
  • Figure 47. Southeast Asia Glaucoma Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 48. India Glaucoma Treatment Sales Value, (2020-2031) & (US$ Million)
  • Figure 49. India Glaucoma Treatment Sales Value by Product (%), 2024 VS 2031
  • Figure 50. India Glaucoma Treatment Sales Value by Application (%), 2024 VS 2031
  • Figure 51. Glaucoma Treatment Industrial Chain
  • Figure 52. Glaucoma Treatment Manufacturing Cost Structure
  • Figure 53. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 54. Bottom-up and Top-down Approaches for This Report
  • Figure 55. Data Triangulation
  • Figure 56. Key Executives Interviewed